- Scholarly Journal
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results
PDF
CiteCite
Copy URL
https://www.proquest.com/scholarly-journals/palazestrant-novel-oral-complete-estrogen/docview/3227648849/se-2?accountid=208611
PrintAll Options